Background-The potential to save money within a short time frame provides a more compelling "business case" for quality improvement than merely demonstrating cost-effectiveness. Our objective was to demonstrate the potential for cost savings from improved control in patients anticoagulated for atrial fibrillation. Methods and Results-Our population consisted of 67 077 Veterans Health Administration patients anticoagulated for atrial fibrillation between October 1, 2006, and September 30, 2008. We simulated the number of adverse events and their associated costs and utilities, both before and after various degrees of improvement in percent time in therapeutic range (TTR). The simulation had a 2-year time horizon, and costs were calculated from the perspective of the payer.
A trial fibrillation (AF) is a common condition and a leading cause of ischemic stroke. 1, 2 The benefit of long-term anticoagulation with warfarin to prevent ischemic stroke in patients with AF is well established. [3] [4] [5] [6] However, the anticoagulation that is actually provided leaves much room for improvement. 7 Quality of anticoagulation can be measured by percent time in the therapeutic range (TTR). 8, 9 Higher TTR has been linked with lower rates of ischemic stroke, major hemorrhage, and death. 10, 11 Although improving TTR would have benefits, payers may be hesitant to invest the time, effort, and resources required for a quality improvement (QI) program. In particular, payers are generally less interested in questions of longterm cost-effectiveness, focusing instead on traditional business considerations of maximizing short-term profit-ability. Because the Veterans Health Administration (VA) is considering a QI program to increase TTR, we undertook to study whether a "business case" can be made for such a program, that is, whether it has the potential to save money in the short term.
We therefore used our Veterans AffaiRs Study to Improve Anticoagulation (VARIA) data base to identify 67 077 patients with AF receiving anticoagulation from the VA over a 2-year period. We simulated the number of adverse events that would be prevented in this population through improved TTR as well as the resulting cost savings and utility gains. We hypothesized that potential cost savings to the payer (the VA), mostly from preventing ischemic strokes, would constitute a compelling business case for this QI program.
WHAT IS KNOWN
• Improved control of oral anticoagulation could prevent many adverse events, which would improve patient health and could potentially produce cost savings for payers. • Cost savings from adverse events averted could at least partly defray the costs of a quality improvement program to improve anticoagulation control.
WHAT THE STUDY ADDS
• Using data from a real cohort of Ͼ60 000 patients anticoagulated for atrial fibrillation in the Veterans Health Administration, we simulated the number of adverse events that might be prevented by slight, moderate, and large improvements in anticoagulation control. • Even assuming a small improvement in control and even with other conservative assumptions, the shortterm cost savings from averted events would likely be much larger than the historical cost of most quality improvement programs. • Because improved anticoagulation control has the potential to produce short-term savings from the payer's perspective while improving patient health, pursuing this goal should be a top priority for the Veterans Health Administration and other systems of care.
Methods

Inclusion Criteria and Calculation of Percent Time in Range (TTR)
The data base for this study has been described previously. 9, 12 VARIA included all patients deemed to be receiving oral anticoagulation therapy from the VA between October 1, 2006, and September 30, 2008, according to the criteria described below. The study was approved by the Institutional Review Board of the Bedford VA Medical Center. There are 128 sites of care in the VA system. We included 100 of these sites and excluded the remaining 28 because their international normalized ratio (INR) values were not captured reliably in VA data bases. For the current study, we limited our data base to patients who were experienced users of warfarin, that is, who had used it for at least 6 months. We defined each patient's date of warfarin initiation as the first INR value Ͼ1.2 or the first outpatient warfarin fill, whichever came first. It would be extremely unusual for a patient to record an INR value Ͼ1.2 unless he or she had taken warfarin. We then stratified the sample into inception time (the first 6 months of warfarin therapy for each patient) and experienced time (any time thereafter).
We included INR tests within the VA when patients were "on warfarin": that is, when a patient was either (1) "in possession" of warfarin or (2) having INR tests every 42 days. We defined the period of warfarin possession as the duration of the most recent VA prescription for warfarin, plus 30 days. We calculated TTR using the Rosendaal method, 13 which uses linear interpolation to calculate the percentage of time during which the INR was between 2 and 3. 13
Estimates of Adverse Event Risks and Their Relationship to Clinical Characteristics
We focused on 3 adverse events: ischemic stroke, major hemorrhage, and death. We relied on estimates from randomized, controlled trials and observational studies, published in English, that reported all of the following: the anticoagulation control achieved by patients receiving adjusted-dose warfarin; sufficient information to compute rates for at least 1 category of adverse events (ie, number of events and person-time of observation); and information on the proportion of patients with congestive heart failure, hypertension, age Ͼ75 years, diabetes mellitus, and prior stroke or transient ischemic attack.
We identified studies using the literature review conducted by the American College of Chest Physicians Guidelines Group in their most recent guidelines for stroke prevention in AF. 5 This review included all randomized and observational studies of patients receiving adjusted-dose warfarin for stroke prevention in AF from 1950 through 2008. We characterized patients' risk of adverse events using the CHADS2 score. 14 CHADS2 stands for Congestive heart failure, Hypertension, Age Ͼ75 years, Diabetes, and prior Stroke. Patients are assigned 1 point for each of the first 4 risk factors, and 2 points for prior stroke; scores vary from 0 to 6. CHADS2 scores are predictive of the risk of ischemic stroke 14 as well as major hemorrhage [15] [16] [17] and are widely used by clinicians and researchers to summarize stroke risk in AF.
The included studies are listed in Table 1 . In total, 18 studies reported rates of ischemic stroke and major hemorrhage 18 -35 ; of those, 14 studies also reported all-cause mortality. 18 -31 For each study, we computed the average CHADS2 score of the included patients. 14 We then used Poisson regression to model the annual rate of each adverse event type as a function of study average CHADS2 score. We assumed that these risks increase exponentially as the CHADS2 score increases, as was shown in the original CHADS2 study. 14 We used the CHADS2 score not only in its original sense (as a predictor of ischemic stroke risk) but also to predict the risk of other adverse events (ie, major hemorrhage and all-cause mortality). The supposition that patients with higher CHADS2 scores have higher rates of all-cause mortality is reasonable but has not been empirically demonstrated. When we subsequently used these models to predict the annual rate of events for individual patients, we substituted each patient's actual CHADS2 score for the study average CHADS2 score. The parameter estimates for these Poisson regressions are shown in Table 2 . The pseudo R 2 values for meta-regressions of stroke, major hemorrhage, and death were 0.16, 0.19, and 0.19, respectively.
Estimates of the Effects of TTR on Adverse Event Risks
We then estimated the relationships between TTR and the rates of our 3 adverse events, using analysis from White et al. 11 Although White reported the relationship between TTR and outcomes using tertiles, we used additional information from another study that analyzed the same data sets 36 to produce a continuous plot for event rates as a function of TTR ( Figure 1 ). To model the predicted event rates for each patient, we predicted each event rate for each patient based on his/her CHADS2 score. We then adjusted this rate on the basis of the patient's TTR.
Simulating the Adverse Events for the VA Population
We constructed a simulation model to predict the likelihood of each type of adverse event given current TTR levels (the "status quo") over a 2-year period and used it to explore how improvements in TTR levels would reduce adverse events. First, we predicted the 2-year event rates for each patient on the basis of his or her CHADS2 score and TTR level, as described above, then summed these event rates to describe the overall rate of any event occurring. We converted this summed rate to a daily probability assuming a constant hazard (exponential model). We then drew random numbers to determine whether any event had occurred each day, and, if yes, then of what type. We assumed that 16% of major hemorrhages are intracranial, as per O'Brien et al. 37 We right-censored patients who did not have an event within the 2-year analysis window. We repeated the simulation 1000 times to generate 95% confidence intervals.
Simulating the Benefits of Improvements in TTR for the VA Population
At this point, each patient was defined by 2 parameters that determined his risk of adverse events: CHADS2 score and TTR. We then altered the status quo by assuming that a QI program had increased TTR, ranging from a 2.5% absolute improvement in TTR to a 20% absolute improvement. Our estimate for the approximate magnitude of this change is based on a meta-analysis, which showed that dedicated anticoagulation clinics achieve a TTR 8.9% higher than management by individual clinicians. 7 It is reasonable to expect that an intervention to improve VA anticoagulation clinics could improve TTR by a similar margin. We assumed that all patients in the data set would have an equal improvement in TTR. Some patients began with a very high TTR at baseline; if the incremental improvement had exceeded a TTR of 100%, some of the postulated improvement was "lost."
Costs and Utilities
For cost and utility estimates, we relied on published literature (Table 3) , especially a cost-effectiveness analysis published by O'Brien and Gage. 37 We calculated the cost savings and health benefits of different degrees of improvement in TTR, compared with the status quo (ie, baseline TTR), based on the number of events averted. We included costs for ongoing warfarin therapy and for adverse events that might be prevented by or caused by warfarin therapy. Costs were expressed in 2008 dollars and were inflationadjusted when their original sources reported costs from other years. 38, 39 Utilities were expressed in terms of quality-adjusted life-years (QALYs), a measure that combines longevity and morbid-ity. 39 These utilities were derived from a population of patients with AF who are similar to our study population in most respects. Given the short time horizon of the analysis (2 years), we report undiscounted costs and QALYs.
Sensitivity/Uncertainty Analyses
We performed 1-way sensitivity analyses on all inputs to the model, including the relationship between CHADS2 scores and event rates, the relationship between TTR and event rates, costs, and utilities. We also performed 2-way sensitivity analyses using pairs of variables with large effect sizes in the 1-way sensitivity analyses.
Although White and others have reported considerable mortality benefits from improved TTR, 11, 40, 41 we suspect that these are overestimates of the effect size. Although it is logical that deaths caused by ischemic stroke or major hemorrhage would be prevented, we suspect that these estimates are inflated by the inclusion of other causes of death that would not be prevented by improved anticoagulation control. The reason for this would be that sicker patients have lower TTR 12 and higher rates of all-cause mortality, some of which is unrelated to excessive or insufficient anticoagulation. Therefore, we ran an additional set of analyses under the extreme assumption that improved TTR has no impact on all-cause mortality-not because we think this is likely, but simply to explore the fullest possible impact of this input on our results.
Finally, we performed a probabilistic sensitivity analysis (via Monte Carlo simulation), simultaneously varying all of our parameters on the basis of their uncertainty distributions, described by their plausible ranges (Table 3) for 1000 iterations. For the probabilistic sensitivity analyses, we assumed beta distributions for utilities, triangular distributions for costs, and normal distributions for the Patient characteristics are given in percentages, and rates are given in events per 100 patient-years. *For some studies, the average age was reported along with the standard deviation, but the proportion of patients age Ͼ75 years was not directly reported. For these studies, proportion with age Ն75 years was estimated by assuming that age was normally distributed.
relationships between CHADS2 or TTR and adverse event rates. All analyses were undertaken with Stata/SE 10.1 (StataCorp, College Station, TX). Drs Rose and Goldhaber-Fiebert had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Results
Patients
Our population consisted of 67 077 patients anticoagulated for AF between October 1, 2006, and September 30, 2008 (Table 4 ). Patients were overwhelmingly male (99%), with a mean age of 72.7 years. Patients had considerable comorbid illness: 41% had diabetes, 37%, had heart failure, and 20% had prior stroke or transient ischemic attack. Many had high CHADS2 scores, indicating substantial risk for ischemic stroke and other adverse events. Anticoagulation control in the overall population was fair (mean TTR, 62.4%). Patients in the lowest tertile had TTR Ͻ55.6%; those in the highest tertile had TTR Ͼ73.4%.
Simulation of Improved Control and Impact on Adverse Events
In the status quo analysis, we simulated adverse events for all 67 077 patients according to their actual observed TTR ( Table 5 ). During the 2-year study, 23.1% of patients (95% confidence interval [CI], 22.8 to 23.4) had any adverse event. Improving TTR by 2.5% averted 584 adverse events (95% CI, 302 to 883). These included 96 ischemic strokes (95% CI, Ϫ74 to 258), 136 major hemorrhages (95% CI, Ϫ24 to 289), and 352 deaths (95% CI, 126 to 584). Improving TTR by 5% averted 1114 adverse events (95% CI, 825 to 1389). These included 183 ischemic strokes (95% CI, 8 to 346), 269 major hemorrhages (95% CI, 118 to 416), and 662 deaths (95% CI, 435 to 869). Larger improvements in TTR were associated with even greater benefits.
Costs and Utilities/Sensitivity Analyses
Cost savings and utility gains from different levels of TTR improvement are shown in Table 5 . Increasing TTR by 5% saved $15.9 million (95% CI, 3.2 to 28.4) and gained 863 QALYs (95% CI, 575 to 1154). Larger improvements in TTR had progressively greater benefits in terms of cost savings and utility gained. We also found that a QI program for oral anticoagulation is very likely to be cost-effective, although the cost of the program and its effectiveness in improving TTR cannot be known in advance. For example, if the QI program achieved a 5% improvement in TTR (a modest result), the program could cost as much as $59 million to implement and still achieve cost-effectiveness at the traditional $50 000/QALY threshold given our 2-year time horizon.
One-way sensitivity analyses are summarized in the online-only Data Supplement Appendix. Varying the cost inputs did not meaningfully alter our results, with the possible exception of the monthly cost of an ischemic stroke with moderate-severe sequelae (example: increasing TTR by 5% saved between $12.2 to $22.7 million, depending on this one input). Varying the utility inputs did not meaningfully alter our results regarding expected utility gains. Varying the relationships between CHADS2 scores and events, or between TTR improvement and events, had the greatest impact on results. Gradients for ischemic stroke had the greatest impact on cost savings: For example, the savings from improving TTR by 5% varied from $8.3 to $35.3 million, depending on the relationship with CHADS2 and from $4.8 to $26.7 million, depending on the relationship with TTR. Gradients for death had the greatest impact on utility gains; for example, the gains from improving TTR by 5% varied from 532 to 1378 QALYs, depending on the relationship with CHADS2 and from 338 to 1230 QALYs, depending on the relationship with TTR. In the most extreme version of this sensitivity analysis, we assumed that changes in TTR had no impact on the risk of death. Predictably, this greatly reduced utility gains; for example, improving TTR by 5% gained 863 QALYs under the base case scenario and only 44 QALYs under this alternative scenario. Cost savings were largely unaffected by this maneuver, leaving the business case for quality improvement intact.
We also performed 2-way sensitivity analyses among the 3 variables with the largest impact on cost in the 1-way sensitivity analyses, including the relationship between CHADS2 score and stroke risk, the relationship between TTR and stroke risk, and the monthly cost of caring for a patient with moderate-severe stroke sequelae. In general, only extreme changes in these inputs had a sizeable impact on the overall cost savings. For example, the combined relationship between TTR, CHADS2, and stroke risk reduced estimated cost savings by Ͼ33% only if either improving TTR had no effect on stroke risk regardless of the relationship between CHADS2 and stroke risk or else if both improving TTR and higher CHADS2 scores had little effect on stroke risk.
Probabilistic sensitivity analyses confirmed that improving TTR is likely to result in benefit, although the exact size of the benefit might vary (Figure 2 ). For example, improving TTR by 5% was 76% likely to result in a savings of Ն$10 million and 97% likely to result in a utility gain of Ն500 QALYs. Of note, a very small improvement in TTR (2.5%) failed to save money approximately 6% of the time. Therefore, to ensure a high probability of being cost saving, a QI program would need to improve TTR by Ն3%.
Discussion
Improving the quality of oral anticoagulation for patients with AF can avert adverse events including ischemic stroke, major hemorrhage, and death. 11 We therefore simulated the effects of a program to improve anticoagulation control in the VA. In this population, even a modest improvement in TTR (5%) Major hemorrhage other than ICH 0.80 0.6-0.9
ICH indicates intracranial hemorrhage. Costs are given in 2008 dollars. Utilities are given in QALYs and are reported per patient per year. One QALY is a full year of life in perfect health; a state of death is worth 0 QALYs, and a year of life with less than perfect health is valued as stated in the table. A major hemorrhage other than ICH causes the listed decrement in utility for only 1 month after the acute event, whereas strokes with sequelae cause the listed decrement in utility until the end of the study.
would be expected to avert 1114 adverse events over 2 years, many of them fatal. We estimated that this change would result in a savings of $15.9 million and a gain of 863 QALYs over our 2-year study period. Even for a system as large as the VA, the cost of QI programs does not approach tens of millions of dollars. For example, the highly successful Translating Initiatives in Depression into Effective Solutions (TIDES) program has greatly improved management and outcomes for VA patients with depression. 42 The total cost of creating and implementing TIDES was recently estimated at $282 000. 43 Therefore, it seems likely that there is a compelling business case for our proposed QI initiative. Although our study is based on a VA population, its lesson would seem to apply to any integrated health care organization.
Anticoagulation therapy for AF is currently undergoing a major change, as dabigatran, the first serious competitor to warfarin, has recently received Food and Drug Administration approval. The RE-LY study showed that dabigatran is slightly superior to warfarin; for example, one would need to treat 357 patients with dabigatran (150 mg) to prevent 1 more ischemic stroke than warfarin would have prevented. 44 Although dabigatran is expected to improve patient convenience, it will be much more expensive than warfarin, even considering the cost of monitoring warfarin therapy. 45, 46 It is likely that the small improvement in outcomes associated with dabigatran can be matched, or nearly matched, by a quality improvement program such as the one simulated here, but at a fraction of the cost. In other words, it may be easier to make a business case for QI in anticoagulation than for dabigatran. Our group plans to examine this issue.
We may have underestimated the benefits of improved TTR because of several of our assumptions. First, we only examined the impact of improved TTR for patients anticoagulated for AF because this is the condition for which we best understand the relationship between TTR and outcomes. 11 However, only about half of all patients receiving anticoagulation in the VA have AF, 12 and patients anticoagulated for other indications also achieve superior outcomes with improved control. 47, 48 Any program to improve TTR would benefit these patients as well, though the magnitude of cost savings or cost effectiveness remains to be determined.
Second, given the available trial-based data on effectiveness, 18 -35 we limited our study to a 2-year time horizon. However, preventing events such as ischemic stroke or major hemorrhage often provides cost and utility benefits for more than 2 years, another source of underestimated benefit. A third conservative feature of this study is that we censored patients after a first adverse event because this is how study outcomes are generally reported. 18 -35 However, patients can have several adverse events, leading to additional costs. A fourth assumption is that we did not consider transient ischemic attacks or minor hemorrhages because most trials do not report these events. Improved TTR should reduce the rates of these events as well. Finally, we did not consider the fact that improved TTR is likely not only to reduce the number of adverse events but also the severity of the events that are not prevented. We did not consider these effects because we lacked solid estimates for effect sizes, but their omission would also tend to underestimate the benefits of improved TTR. This study has important strengths. First, as mentioned above, a number of underlying assumptions suggest that we have, if anything, underestimated the benefits of improved TTR. Second, we used a large data base of VA patients about which we have relatively complete data, especially regarding their CHADS2 risk for ischemic stroke. This allowed us to perform a detailed patient-level simulation to examine the impact of different degrees of TTR improvement in this population. Finally, much is known about the relationship between anticoagulation control and outcomes in AF, which is why we chose to focus on this condition in particular.
However, our study also has limitations. First, patient comorbidities were assessed using ICD-9 scores, which can be inaccurate. However, the CHADS2 scores that we ascribed to our population are well within the realm of what has been reported previously. 18 -35 Second, we used CHADS2 not only as it was originally intended that is, as a risk score for ischemic stroke, 14 but also as a risk score for major hemorrhage and all-cause mortality; however, some literature supports using CHADS2 as a risk score for major hemorrhage. [15] [16] [17] When we used CHADS2 to risk-stratify for mortality, we used it as an all-purpose composite comorbidity score, similar to others that have been used in many prior studies. 49 This was necessary in large part because most of our source studies only reported these comorbidities. 18 -35 Third, VA cost data are somewhat unique in that the VA does not usually bill for services. Therefore, we chose to use Medicare cost estimates for our study 37 to enhance generalizability to most settings. Fourth, our utility estimates are derived from a general population 37 rather than a VA popu-lation, and we did not include the inherent disutilities of comorbid conditions, old age, and ill health. This omission somewhat overstates benefits, although the extent of this is limited by our 2-year time horizon. Fifth, our estimates for event rates by CHADS2 score were derived from meta-analysis at the study level; however, in our data set we applied these coefficients at the individual patient level. To the extent that components of the CHADS2 score are correlated within individuals, our study-level analysis may in fact underestimate the risk of events with increasing CHADS2 scores at the individual level.
In conclusion, we modeled the possible benefits of a program to improve anticoagulation control for patients with AF in a large, integrated health care system. We found that such a program would be cost-saving even if it had only a minimal impact on control and even if it were considerably more expensive to implement than most QI programs have historically been. Our results suggest that the VA and other integrated healthcare systems should strongly consider implementing such a program. It is unusual to have an opportunity to save money while improving patient outcomes; this study describes such an opportunity.
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